Drugs / Testosterone Enanthate
Testosterone Enanthate
also known as
Androtardyl · delatestryl · NSC-17591 · Primoteston depot · TEST · Testosterone enantate · Testosterone enanthate ciii · Testosterone enanthate component of ditate-ds · +3 more
Small molecule targets AR via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | DELATESTRYL | — | 1979-08-02 – 1980-02-01 | fda.gov ↗ |
| Approved | US (FDA) | DELATESTRYL | — | 1953-12-24 | fda.gov ↗ |
Trials 27
1952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03123913 | Dec 2017 → Mar 2022 | facioscapulohumeral muscular dystrophy | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT02233751 | Sep → Oct 2014 | hypogonadism | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01962454 | May 2014 → Mar 2015 | hypoproteinemia, hypercatabolic | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01887418 | Sep 2013 → Jan 2014 | hypogonadism | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 213 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT06594926 | Aug 2024 → Dec 2026 expected | prostate cancer | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04460872 | Jan 2021 → Jan 2026 overdue | hypogonadism, male, male reproductive system disorder, movement disorder, spinal cord injury | North Florida Foundation for Research and Education | Recruiting | No outcome recorded |
| Phase 2 | NCT04363164 | Aug 2020 → Jul 2027 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT03516812 | Aug 2018 → Mar 2021 | castration-resistant prostate carcinoma, prostate adenocarcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT03522064 | Jul 2018 → Sep 2026 overdue | castration-resistant prostate carcinoma | St Vincent's Hospital, Sydney | Recruiting | No outcome recorded |
| Phase 2 | NCT02248701 | Apr 2017 → Aug 2021 | hypogonadism, male reproductive system disorder, spinal cord injury | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02777242 | Jun → Aug 2016 | hypogonadism, male | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02286921 | Jan 2015 → Oct 2018 | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Missed primary |
| Phase 2 | NCT02090114 | Aug 2014 → Nov 2021 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Met primary |
| Phase 2 | NCT00695110 | Jun → Dec 2008 | hypogonadism, male | Clarus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00475501 | Jan 2007 → Mar 2012 | benign prostatic hyperplasia, hypogonadism, male, muscular atrophy | VA Office of Research and Development | Completed | Met primary |
| Phase 2 | NCT00260143 | May 2003 → Jun 2006 | HIV wasting syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2 | NCT00001079 | ? → Dec 2002 | HIV wasting syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT06689085 | Mar 2025 → Mar 2028 expected | hypogonadism, male | Halozyme Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT02504541 | Jul 2015 → Jun 2016 | hypogonadism, male | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02159469 | Jul 2014 → Feb 2015 | hypogonadism, male | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01275365 | May 2011 → Jan 2017 | — | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 3 | NCT00070733 | Aug 2003 → Jun 2005 | sexual disorder | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02734238 | Apr 2016 → Dec 2017 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 4 | NCT01417364 | Jan → Dec 2016 | muscular atrophy | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01601327 | Jan 2008 → Mar 2012 | hypogonadotropic hypogonadism | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07568574 | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT04971447 | Aug 2022 → Sep 2023 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT00878995 Comparator | Jun 2009 → Jun 2014 | hypoproteinemia, hypercatabolic, squamous cell carcinoma | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT01017458 Comparator | Jun 2007 → Aug 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00399165 Comparator | Nov 2006 → May 2007 | — | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT02697188 Comparator | Nov 2007 → Apr 2008 | hypogonadism | Clarus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03674320 Comparator | Dec 2021 → Aug 2024 | chronic obstructive pulmonary disease | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT00161304 Comparator | Apr 2003 → Aug 2004 | — | Leonard S. Marks, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT04026880 Comparator | Jan 2021 → Jan 2022 | — | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00493987 Comparator | Nov 2002 → Dec 2009 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Testosterone Enanthate | “Pharmacokinetic Study of Testosterone Enanthate” NCT01887418 ↗ |
| Known as | Androtardyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | delatestryl | “delatestryl” NCT02248701 ↗ |
| Known as | NSC-17591 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Primoteston depot | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | TEST | “The objective of this study was to determine the effects of weekly testosterone enanthate (TEST; 200 mg·wk -1 ) injections on energy expenditure, energy substrate oxidation,...” PMID 36563086 ↗ Nov 2022 |
| Known as | Testosterone enantate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosterone enanthate ciii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosterone enanthate component of ditate-ds | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosteroni enantas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Xyosted | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Xyosted (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Action | Activate | “Androgen Receptor agonist” CHEMBL1200335 ↗ |
| Modality | Small molecule | — CHEMBL1200335 ↗ |
| Route | Intramuscular | “testosterone enanthate or matching placebo intramuscularly” PMID 17105798 ↗ Nov 2006 |
| Target | AR | “Androgen Receptor agonist” CHEMBL1200335 ↗ |